Scarica l'app Stockscreener
317.74
0.11%
0.36
Dopo l'orario di chiusura:
318.34
0.60
+0.19%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Amgen Inc Borsa (AMGN) Ultime notizie
Amgen’s Uplizna Approved For Its Largest And Most Competitive Indication Yet - Citeline News & Insights
FDA Grants Orphan Status to Amgen's (AMGN) Blinatumomab for Leuk - GuruFocus
Amgen (AMGN) Receives Maintained Rating, Price Target Lowered to - GuruFocus
FDA Approves Amgen’s UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease - Yahoo Finance
FDA Approves Amgen's Drug For Rare Muscle Disorder - Benzinga
Amgen (AMGN) Gains FDA Nod for Expanded Use of Uplizna in Myasth - GuruFocus
Morgan Stanley Adjusts Amgen Price Target to $304 From $329, Maintains Equalweight Rating - marketscreener.com
Amgen wins FDA nod for Uplizna in myasthenia gravis (AMGN) - Seeking Alpha
Quantinno Capital Management LP Purchases 19,014 Shares of Amgen Inc. $AMGN - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Lowers Holdings in Amgen Inc. $AMGN - MarketBeat
Peapack Gladstone Financial Corp Has $30.82 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Sei Investments Co. - MarketBeat
FDA approves Amgen’s UPLIZNA for generalized myasthenia gravis - Investing.com
FDA Approves Amgen's UPLIZNA for New Myasthenia Gravis Treatment - GuruFocus
FDA approves Amgen’s UPLIZNA for generalized myasthenia gravis By Investing.com - Investing.com Australia
Amgen (NASDAQ:AMGN) gets FDA OK for Uplizna as first CD19 B-cell therapy for gMG - Stock Titan
The Manufacturers Life Insurance Company Reduces Position in Amgen Inc. $AMGN - MarketBeat
NewEdge Advisors LLC Grows Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Prolynx Secures $70 Million Series A to Advance Portfolio of Ultra-Long-Acting Obesity Candidates and Appoints Chris Boulton as Chief Executive Officer - GlobeNewswire Inc.
Wells Fargo Maintains Amgen (AMGN) Equal-Weight Recommendation - Nasdaq
Amgen Inc. (NASDAQ:AMGN) Announces Quarterly Dividend of $2.52 - MarketBeat
Amgen describes new GTPase KRAS mutant inhibitors - BioWorld MedTech
Amgen: Improving Balance Sheet Is Bringing The Stock Close To Being A "Buy" (NASDAQ:AMGN) - Seeking Alpha
Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
Intact Investment Management Inc. Sells 10,800 Shares of Amgen Inc. $AMGN - MarketBeat
Ossiam Sells 13,818 Shares of Amgen Inc. $AMGN - MarketBeat
Wells Fargo Adjusts Price Target on Amgen to $325 From $300, Maintains Equalweight Rating - marketscreener.com
HSBC Adjusts Price Target on Amgen to $425 From $381, Maintains Buy Rating - marketscreener.com
Amgen (AMGN) to Participate in Upcoming Virtual Meeting - GuruFocus
Amgen Announces Dividend for the First Quarter of 2026, Payable on March 6, 2026 - marketscreener.com
Amgen Raises Quarterly Dividend to $2.52 a Share From $2.38, Payable March 6 to Shareholders of Record as of Feb. 13 - marketscreener.com
Amgen declares $2.52 per share dividend for first quarter 2026 By Investing.com - Investing.com UK
AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND - PR Newswire
Key facts: Amgen invests $900M in Ohio; hosts Clinical Research Forum in UAE - TradingView
State Street Corp Increases Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by SVB Wealth LLC - MarketBeat
Who Owns Amgen? Top Shareholders and Recent Insider Trades - TIKR.com
Fayez Sarofim & Co Acquires 18,213 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Purchased by Daiwa Securities Group Inc. - MarketBeat
Bank of Nova Scotia Has $29.83 Million Stake in Amgen Inc. $AMGN - MarketBeat
Axa S.A. Purchases 103,665 Shares of Amgen Inc. $AMGN - MarketBeat
Rep. David Taylor Sells Amgen Inc. (NASDAQ:AMGN) Stock - MarketBeat
Amgen Inc. $AMGN Shares Bought by L2 Asset Management LLC - MarketBeat
Gabelli Funds LLC Sells 3,150 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Position Boosted by Federated Hermes Inc. - MarketBeat
Amgen Inc.'s (NASDAQ:AMGN) Intrinsic Value Is Potentially 68% Above Its Share Price - Yahoo Finance
Amgen Inc. $AMGN Shares Bought by Cerity Partners LLC - MarketBeat
Amgen Inc. $AMGN Shares Sold by California Public Employees Retirement System - MarketBeat
Amgen (NASDAQ:AMGN) Cut to "Buy" at Wall Street Zen - MarketBeat
Has the Market Fully Priced In Amgen’s Rally After Pipeline and Regulatory Milestones? - simplywall.st
BMO Capital Lifts Amgen (AMGN) Price Target as MariTide Outlook Strengthens - Finviz
Peptide Therapeutics Market Size to Reach USD 82.19 Billion by 2032; Surging Requirements for Targeted Medicines in Oncology Augment Market Expansion - GlobeNewswire Inc.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock - sharewise.com
A Closer Look at Amgen (AMGN) Valuation After Its 12-Month 28% Share Price Gain - simplywall.st
Erste Group upgrades Amgen stock rating to Buy from Hold on obesity drug - Investing.com
Amgen (NASDAQ:AMGN) Rating Increased to Buy at Erste Group Bank - MarketBeat
Amgen Named Official Biotech Partner by Los Angeles Sports & Entertainment Commission (LASEC) Ahead of FIFA World Cup 2026 - Amgen
Tema Etfs LLC Has $3.62 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
What makes Amgen Inc. (AMG0) stock appealing to growth investorsMarket Performance Recap & Smart Money Movement Alerts - Newser
Is Amgen Inc. (AMG0) stock overpriced at current multiplesEarnings Risk Report & Long-Term Investment Growth Plans - Newser
First Trust Advisors LP Sells 21,347 Shares of Amgen Inc. $AMGN - MarketBeat
Beutel Goodman & Co Ltd. Raises Position in Amgen Inc. $AMGN - MarketBeat
Baird Financial Group Inc. Cuts Position in Amgen Inc. $AMGN - MarketBeat
Amundi Raises Stake in Amgen Inc. $AMGN - MarketBeat
Why Is Amgen (AMGN) Up 8% Since Last Earnings Report? - Yahoo Finance
Pharmaceutical Marketing Industry Trends and Emerging Opportunities 2025-2032 Featuring Syneos Health, McCann Health, Amgen, AXPIRA, Pfizer and MoreResearchAndMarkets.com - Business Wire
Amgen (NASDAQ:AMGN) Shareholders Have Earned a 12% CAGR Over the Last Five Years - 富途牛牛
Amgen: Stagnation And The IRS Are Coming (NASDAQ:AMGN) - Seeking Alpha
Does Amgen Stock Lead the Pack? - Trefis
EverSource Wealth Advisors LLC Cuts Position in Amgen Inc. $AMGN - MarketBeat
Guggenheim Capital LLC Boosts Stake in Amgen Inc. $AMGN - MarketBeat
Will Strong Q3 Beat And Pipeline Updates Change Amgen's (AMGN) Future Earnings Narrative? - simplywall.st
BMO Capital Maintains Amgen (AMGN) Outperform Recommendation - Nasdaq
Amgen (NASDAQ:AMGN) Reaches New 12-Month HighStill a Buy? - MarketBeat
Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza - Benzinga
2.28%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):